-+ 0.00%
-+ 0.00%
-+ 0.00%

BioStem Q2 FY26 GAAP net loss widens to $9 million; revenue rises 29% to $7.9 million vs Q1

PUBT·08/12/2026 20:13:03
Listen to the news
BioStem Q2 FY26 GAAP net loss widens to $9 million; revenue rises 29% to $7.9 million vs Q1
  • BioStem posts Q2 2026 net revenue of USD 7.9 million, up 29% sequentially.
  • GAAP swings to a net loss of USD 9 million, or USD 0.52 a share.
  • Gross profit totals USD 4.84 million, with gross margin flat at 61% versus Q1 2026.
  • Operating expenses rise to USD 13.24 million, driven primarily by an expanding commercial team and infrastructure.
  • Uplisted to Nasdaq Capital Market on Aug. 7; full-year 2026 revenue outlook lifted to USD 26 million-USD 29 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biostem Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9809012) on August 12, 2026, and is solely responsible for the information contained therein.